Prestige Biopharma Limited, announced that its first-in-class antibody PBP1510 has acquired an International Nonproprietary Name (INN) of ‘Ulenistamab’ and was placed on the INN Recommended List by the World Health Organization (WHO).
Prestige Biopharma Limited first-in-class antibody has acquired an International Nonproprietary Name (INN) of ‘Ulenistamab’. INN-Ulenistamab, which is also known as a generic name, facilitates the identification of pharmaceutical substances or active pharmaceutical ingredients. Each INN is a unique name that is globally recognized and is public property. The name is given through a thorough examination and discussion on the drug by the WHO and INN experts.
PBP1510 (INN-Ulenistamab) is an anti-PAUF monoclonal antibody for pancreatic cancer treatment. It effectively inhibits the growth and progression of pancreatic cancer by blocking PAUF (Pancreatic Adenocarcinoma Up-Regulated Factor), which is responsible for the rapid growth of tumors.
Lisa S. Park, CEO of Prestige BioPharma said, “With its INN- Ulenistamab, PBP1510 is one step closer to commercialization. Not to mention pancreatic cancer has the highest mortality rate of all major cancers, we will try our utmost with PBP1510 so that it could provide significant benefit in all patients affected by PAUF-positive pancreatic cancer.”
In 2020, PBP1510 (INN-Ulenistamab) was granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA) and
Korean MFDS. Currently, it is in Phase 1/2a clinical trials in France and Spain.
About Prestige Biopharma
Prestige Biopharma focuses on the development of biosimilars and first-in-class antibody drugs as well as vaccines for infectious diseases. With decades of R&D and operational experience in drug discovery, Prestige Biopharma expedites future biologics development and commercialization in a concerted approach based on proprietary technologies and scientific capabilities. Prestige strives to become a global innovator through the development of first-in-class antibody therapeutics including PBP1510 anti-PAUF mAb for pancreatic cancer (INN-Ulenistamab) that recently obtained orphan designation from FDA, EMA and MFDS.